Our sister site, Drug Delivery Business News, reported that San Diego-based Dexcom submitted a 15-day version of its G7 continuous glucose monitor (CGM) to the FDA. The technology previously had a wear time of 10 days. This would match it with the recently launched Stelo biosensor, which was developed on the G7 platform and has a 15-day wear time.
The company yesterday evening also reported third-quarter results that topped the consensus forecast. Shares of DXCM were up slightly at the opening of trading today.
Get the full story at our sister site, Drug Delivery Business News.
This story originally ran on Oct. 24, 2024. Updated Oct. 25 with the next-day stock price.
